Study of 18 F-fluciclovine PET for serial assessment of glioblastoma tumor volumes during surgery and radiotherapy - Takeaways - MDSpire

Study of 18 F-fluciclovine PET for serial assessment of glioblastoma tumor volumes during surgery and radiotherapy

  • By

  • Samir A. Dagher

  • Jason M. Johnson

  • Rania M.M. Mohamed

  • Shehbaz Ansari

  • Osama Mawlawi

  • Ho-Ling Liu

  • Max Wintermark

  • Dawid Schellingerhout

  • Lesley Flynt

  • Debra N. Yeboa

  • Jeffrey S. Weinberg

  • Sherise D. Ferguson

  • Maria K. Gule-Monroe

  • July 1, 2025

  • 0 min

Share

  • 1

    Glioblastoma has a poor prognosis, with a 1-year survival rate of 42.9% and a 5-year survival rate of only 6.9%.

  • 2

    18 F-Fluciclovine PET provides improved detection of gliomas compared to conventional MRI, revealing larger tumor volumes.

  • 3

    This study aims to compare tumor volumes from 18 F-Fluciclovine PET, T1C, and FLAIR at multiple treatment timepoints.

  • 4

    The study hypothesizes that hypermetabolic volumes will exceed T1C volumes but remain smaller than FLAIR volumes.

  • 5

    A total of 8 participants were enrolled due to challenges in recruitment, including the COVID-19 pandemic.

Original Source(s)

Study of 18 F-fluciclovine PET for serial assessment of glioblastoma tumor volumes during surgery and radiotherapy

  • by Samir A. Dagher, Jason M. Johnson, Rania M.M. Mohamed, Shehbaz Ansari, Osama Mawlawi, Ho-Ling Liu, Max Wintermark, Dawid Schellingerhout, Lesley Flynt, Debra N. Yeboa, Jeffrey S. Weinberg, Sherise D. Ferguson, Maria K. Gule-Monroe

  • July 1, 2025

Related Content

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy